🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Placebo tablet matching acetylsalicylic acid, MIGOUTINE 0,5 mg, comprimé pelliculé, ACETYLSALICYLIC ACID , Placebo tablet matching migoutine 0,5 mg, comprimé pelliculé

    The George Institute

    Type 2 diabetic patients with no prior cardiovascular (CV) events

    phase 3 small molecule active

    1 trial

  2. Placebo tablets to match S95032 drug product are supplied as white to off-white, round (10 mg) and white to off-white oblong (40 mg) film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    The George Institute

    Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

    phase 3 small molecule active

    1 trial

  3. Placebo tablets without active pharmaceutical ingredient closely resembling the imp, Hetrombopag Olamine

    Lacuna Pharma Pty Ltd

    Chemotherapy induced thrombocytopenia

    phase 3 small molecule active

    1 trial

  4. Placebo tablets, ELENESTINIB, ELENESTINIB, ELENESTINIB, ELENESTINIB

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis and SSM

    phase 3 small molecule active

    1 trial

  5. Placebo tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Hoffmann-La Roche

    Small cell lung cancer (SCLC)

    phase 3 small molecule active

    1 trial

  6. Placebo to AIN457 150 mg/ 1 mL Solution for injection in pre-filled syringe. This placebo is an additional/ alternative placebo to placebo to Xolair® (Omalizumab) to ensure continuous supply in the clinical trial. For more details please refer to Note to Assessor located in the “Placebo to AIN457” product shell., OMALIZUMAB , -, Placebo to Xolair® (Omalizumab) 150 mg/ml solution for injection in pre-filled syringe, LOU064, Placebo to Remibrutinib (LOU064) 25 mg film-coated tablet, -

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  7. Placebo to Basimglurant (Microcrystalline Cellulose Spheres (Vivapur 1000) and hard Gelatin Capsule, Opaque white body/Opaque white cap, Size 1), Basimglurant, Basimglurant

    Lacuna Pharma Pty Ltd

    Trigeminal neuralgia, Trigeminal neuralgia

    phase 3 small molecule active

    1 trial

  8. Placebo to Clostridium Botulinum neurotoxin type A (150 kD), CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS

    Merz Therapeutics GmbH

    Chronic migraine

    phase 3 small molecule active

    1 trial

  9. Placebo to Descartes-08, Descartes-08

    Cartesian Therapeutics

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  10. Placebo to Imetelstat, -, -, IMETELSTAT

    Geron Netherlands B.V.

    Myelodysplastic syndromes (MDS)

    phase 3 small molecule active

    1 trial

  11. Placebo to Match Tinlarebant (LBS-008). Placebo tablets will be prepared similarly with microcrystalline cellulose used in place of the active drug substance. The placebo tablet is identical in size, appearance, and other physical properties to the LBS-008 tablet., LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Geographic Atrophy

    phase 3 small molecule active

    1 trial

  12. Placebo to Ponsegromab (PF-06946860), CALCIUM LEVOFOLINATE PENTAHYDRATE, Ponsegromab (PF-06946860)

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 3 small molecule active

    1 trial

  13. Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064

    Novartis Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  14. Placebo to Upadacitinib

    AbbVie

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  15. Placebo to capivasertib, Capivasertib, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Capivasertib, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung

    AstraZeneca AB

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  16. Placebo to match Choline Chloride for Injection, Choline Chloride for Injection

    Protara Therapeutics

    Intestinal Failure

    phase 3 small molecule active

    1 trial

  17. Placebo to match LY, Muvalaplin

    Eli Lilly Co.

    Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  18. Placebo will be provided in size and appearance identical to those containing milsaperidone and will be administered orally., Milsaperidone, Milsaperidone, Milsaperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  19. Placebo with a matching appearance to 100 mg niraparib capsules, filled with an excipient blend for clinical development., NIRAPARIB TOSILATE MONOHYDRATE

    TESARO Bio Netherlands B.V.

    Homologous recombination deficiency advanced ovarian cancer

    phase 3 small molecule active

    1 trial

  20. Placebo, DRY EXTRACT FROM CHASTE TREE FRUITS (7-11:1), EXTRACTION SOLVENT: ETHANOL 70% (V/V)

    Topiloric/Uriadec

    Primary Dysmenorrhea

    phase 3 small molecule active

    1 trial

  21. Placebo, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Lacuna Pharma Pty Ltd

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  22. Placebo, Simvastatina NORMON 40 mg comprimidos recubiertos con película EFG

    The George Institute

    Fibrosis liber, chronic liver disease, alcoholic liver disease

    phase 3 small molecule active

    1 trial

  23. Platelet Rich Plasma

    Hospital Authority, Hong Kong

    Severe Oligoasthenoteratozoospermia

    phase 3 mab completed

    1 trial

  24. Platelet Rich Plasma Injection

    United Therapeutics Europe Ltd

    Osteoarthritis of the Shoulder

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources